Live Q&A: Real-world Tactics to Address Health Inequities in Multiple Myeloma CarePremiere Date: Thursday, November 3, 2022
This activity offers CE credit for:%>
- Medicine (accme)
- Nursing (ANCC)
- Pharmacy (acpe)
- PA (aapa)
- Dietetic Registration (CDR)
All other clinicians will receive a Certificate of Attendance stating this activity was certified for AMA PRA Category 1 Credit™
Credit Expiration Date:
Friday, November 3, 2023
|Joseph Mikhael, MD, MEd, FRCPC, FACP (Moderator)
Professor, Applied Cancer Research and Drug Discovery Division
Translational Genomics Research Institute (TGen)
Chief Medical Officer, International Myeloma Foundation (IMF)
Studio City, CA
|Saad Z. Usmani, MD, MBA, FACP
Chief of Myeloma Service
Chief, Myeloma Service Memorial Sloan Kettering Cancer Center (MSK)
Member, Memorial Sloan Kettering Cancer Center
Attending Physician, Myeloma, Cellular Therapy and Adult BMT
New York, NY
Multiple myeloma has twice the incidence and death rate in Black people, compared with White people. Yet, Black people are half as likely to undergo a stem cell transplantation despite having similar, if not better, survival rates compared to White people, when given standard of care treatment. Chasms in early diagnosis, treatment options and access, survival rate, and more, remain for racial and ethnic underserved populations. A culmination of biases, disparities, and inequities continues a cycle of inadequate oncology treatment for multiple myeloma, thus resulting in delayed diagnosis, and suboptimal clinical management, prognosis, and survival rate.
This live Q&A session is your opportunity to ask questions based on the CME Outfitters BriefCase that focused on identifying the impact of health inequities on patients with multiple myeloma.
At the end of this CE activity, participants should be able to:
- Identify the impact of health inequities on patients with multiple myeloma and develop individual treatment strategies for optimal outcomes.
Supported by an educational grant from the Johnson & Johnson Institute and the Johnson & Johnson Family of Companies.
Physicians, PAs, NPs, nurses/nurse navigators, pharmacists, and dietitians specializing in hematology, pathology, radiology, or primary care.
Provider approved by the California Board of Registered Nursing, Provider Number CEP 15510, for 0.5 contact hours.br>
This program has been submitted to The Commission for Case Manager Certification for approval to provide board certified case managers with 0.5 clock hours.
Dr. Mikhael reports the following financial relationships:
Consultant: Amgen Inc.; Bristol Myers Squibb; GSK; Janssen Pharmaceuticals, Inc.; Karyopharm; Sanofi; and Takeda Pharmaceuticals U.S.A., Inc.
Dr. Usmani reports the following financial relationships:
Advisory Board: AbbVie Inc.; Amgen Inc.; Bristol Myers Squibb Company; Celgene Corporation; EdoPharma; Genentech, Inc.; Gilead Sciences, Inc.; GSK; Janssen Pharmaceuticals, Inc.; Oncopeptides, Inc.; Sanofi; Seattle Genetics, Inc.; Secura Bio; SkylineDx USA, Inc.; Takeda Pharmaceuticals U.S.A., Inc.; and Teneobio, Inc.
Research Support: Amgen Inc.; Array BioPharma Inc.; Bristol Myers Squibb Company; Celgene Corporation; GSK; Janssen Pharmaceuticals, Inc.; Merck & Co., Inc.; Pharmacyclics, Inc.; Sanofi; Seattle Genetics, Inc.; SkylineDx USA, Inc.; and Takeda Pharmaceuticals U.S.A., Inc.
Speakers Bureau: Amgen Inc.; Bristol Myers Squibb Company; Janssen Pharmaceuticals, Inc.; and Sanofi
The following peer reviewer and CME Outfitters staff have no financial relationships:
Faculty of this CE activity may include discussions of products or devices that are not currently labeled for use by the FDA. The faculty have been informed of their responsibility to disclose to the audience if they will be discussing off-label or investigational uses (any uses not approved by the FDA) of products or devices.
Questions about this activity? Call us at 877.CME.PROS (877.263.7767).